1/22/2021

Sufentanil Injection

Reason for the Shortage

- Akorn had Sufenta injection on shortage due to increased demand for the product.
- Hikma stopped marketing sufentanil injection in October 2018.
- Pfizer had sufentanil injection on shortage due to manufacturing delays.

Available Products

- Sufenta solution for injection, Akorn, 50 mcg/mL, 1 mL ampule, 10 count, NDC 17478-0050-01
- Sufenta solution for injection, Akorn, 50 mcg/mL, 2 mL ampule, 10 count, NDC 17478-0050-02
- Sufenta solution for injection, Akorn, 50 mcg/mL, 5 mL ampule, 10 count, NDC 17478-0050-05
- Sufentanil solution for injection, Pfizer, 50 mcg/mL, 1 mL vial, 10 count, NDC 00409-3382-21
- Sufentanil solution for injection, Pfizer, 50 mcg/mL, 2 mL vial, 10 count, NDC 00409-3382-22
- Sufentanil solution for injection, Pfizer, 50 mcg/mL, 5 mL vial, 10 count, NDC 00409-3382-25

Estimated Resupply Dates

- All marketed presentations are available.

Implications for Patient Care

- ASHP has an FAQ on the injectable opioid shortage at https://www.ashp.org/Drug-Shortages/Shortage-Resources/Injectable-Opioid-Shortages-FAQ. This discusses multiple issues including inventory and pharmacy operational strategies

Updated

Updated January 22, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. Created January 12, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2021, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.